Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

10.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.6K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.6K
Trial and Error and Algorithm01:12

Trial and Error and Algorithm

425
A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
425
Epigenetic Regulation01:46

Epigenetic Regulation

33.9K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.9K
GTPases and their Regulation02:14

GTPases and their Regulation

9.9K
Guanine nucleotide-binding proteins (G-proteins), also known as GTPases, are a superfamily of proteins that regulate many cellular processes, such as cell signaling, vesicular transport, and the regulation of cell shape and motility. Mutation or dysfunction of these proteins can lead to disease. There are around 40,000 known G-proteins that can broadly be classified into two groups ‒  small G-proteins consisting of a single domain and large multi-domain G-proteins.
Large G-proteins,...
9.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis.

Ecancermedicalscience·2013
Same author

Experimental demonstration of modulation instability in an optical fiber with a periodic dispersion landscape.

Optics letters·2012
Same author

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.

Leukemia·2012
Same author

BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph(+) acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy.

Blood cancer journal·2012
Same author

Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia.

Blood cancer journal·2012
Same author

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

Leukemia·2012

Related Experiment Video

Updated: Feb 7, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

Main changes in European Clinical Trials Regulation (No 536/2014).

E Tenti1, G Simonetti1, M T Bochicchio1

  • 1Istituto di Ematologia L. and E. Seragnoli, University of Bologna, Italy.

Contemporary Clinical Trials Communications
|July 14, 2018
PubMed
Summary
This summary is machine-generated.

The European Union's Clinical Trials Regulation (EU) No. 536/2014 streamlines research with a unified framework for drug trials. This regulation facilitates cross-border collaboration and encourages development of treatments for rare diseases and pediatrics.

Keywords:
CI, Informed ConsentClinical trialsEC, European CommissionEU, European UnionInterventional studyMA, Marketing authorizationMS, member statesNew regulationReporting member statesrMS, reporting member state

More Related Videos

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

15.5K

Related Experiment Videos

Last Updated: Feb 7, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

15.5K

Area of Science:

  • Regulatory Science
  • Clinical Trial Management
  • Pharmaceutical Policy

Background:

  • The European Commission aims to boost scientific research and industrial progress through updated regulatory frameworks.
  • Existing regulations had gaps, necessitating a uniform approach to clinical trial authorization and assessment across EU Member States.

Purpose of the Study:

  • To introduce and analyze the impact of Regulation (EU) No. 536/2014 on clinical trials within the European Union.
  • To highlight the regulation's role in harmonizing trial authorization, facilitating cross-border cooperation, and encouraging the development of specialized treatments.

Main Methods:

  • Implementation of a new, unified framework for clinical trial authorization across all EU Member States.
  • Introduction of simplified rules for 'low-intervention' clinical trials, including off-label use of authorized medicines with supporting evidence.
  • Establishment of a new electronic EU portal for paperless submission of applications and communications.

Main Results:

  • Creation of a uniform system for clinical trial authorization and single assessment of results.
  • Facilitation of wider clinical testing and enhanced cross-border cooperation.
  • Streamlined rules, including provisions for low-intervention trials, benefiting pediatric and oncological areas.

Conclusions:

  • The new regulation presents a significant challenge for stakeholders due to complex procedures and shorter timelines.
  • It is expected to enhance the EU's role in developing innovative medicines and specialized treatments.
  • The regulation promotes scientific research and industrial progress by standardizing clinical trial processes.